WEHI-539

• UNSPSC Description:

  WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.

• Target Antigen:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/WEHI-539.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(C1=C(CCCOC2=CC=C(CN)C=C2)SC(C3=CC4=C(CCC/C4=N\NC5=NC(C=CC=C6)=C6S5)C=C3)=N1)=O

• Molecular Weight:

  583.72

• References & Citations:

  [1]Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013 Jun;9(6):390-7.|[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.Am J Cancer Res. 2019 Dec 1;9(12):2580-2598.|Breast Cancer Res Treat. 2019 Feb;173(3):585-596.|Cancer Biology. 2020 May.|Cell Death Differ. 2014 Jul;21(7):1170-7. |Cell Death Differ. 2017 Jan;24(1):111-119. |Cell Death Dis. 2017 Dec 13;8(12):3216.|Cell Death Dis. 2023 Oct 28;14(10):705.|Cell. 2014 Dec 18;159(7):1549-62.|Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. |J Ovarian Res. 2016 Apr 14;9(1):25. |Nat Commun. 2016 Mar 9;7:10916.|Nature. 2017 Nov 9;551(7679):247-250. |Oncol Rep. 2019 Dec;42(6):2416-2425.|Pharmacol Res. 2022 Dec 21;187:106628.|Acta Pharmacol Sin. 2024 Aug 26.|bioRxiv. 2023 Aug 5.|Blood. 2014 Dec 4;124(24):3587-96. |Cell Death Dis. 2018 Jan 19;9(2):42.|Cell Rep. 2023 Mar 30;42(4):112324.|Cell. 2014 Dec 18;159(7):1549-62.|Immunity. 2024 Jun 11;57(6):1289-1305.e9.|Int J Cancer. 2018 Feb 1;142(3):584-596.|Malays Appl Biol. (2020) 49(1): 193-197.|Methods Mol Biol. 2018;1711:351-398.|Nat Biotechnol. 2018 Feb;36(2):179-189.|Nat Cancer. 2024 May 30.|Nat Chem Biol. 2022 Jun;18(6):615-624.|Nature. 2017 Nov 9;551(7679):247-250. |Oncotarget. 2018 May 25;9(40):26046-26063.|The Department of Medical Sciences, Harvard University. 2019 Dec.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1431866-33-9